Eris Lifesciences Limited
₹1,159.60-₹4.10 (-0.4%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹20,131 Cr
- P/E
- 71.4x
- EV / EBITDA
- 45.5x
- Revenue
- ₹1,698 Cr
- Net margin
- 20.2%
- ROCE
- 8.9%
Price chart
Technical chartScreen technicals →-28.4% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -2.6%
- 3M
- -15.7%
- 6M
- -12.3%
- 1Y
- -28.4%
- 5Y
- +42.4%
52-week range
Day change -₹4.10 (-0.4%) from ₹1,164 to ₹1,160 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in ERIS, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Strong cash conversion — FCF/PAT ratio of 4.45
Concerns1
- Operating margin declining for 3 consecutive years (38.0% → 31.0% → 29.0%)
Rule-based from financial data. Not advice.
About the company
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally.
Read moreShow less
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.
- Sector
- Healthcare
- Shares outstanding
- 13.6 Cr shares
- ISIN
- INE406M01024
- BSE code
- 540596
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹20,131 Cr
- P/E
- 71.4x
- P/B
- 7.3x
- EV / EBITDA
- 45.5x
- EV / Sales
- 15.0x
- P/S
- 13.5x
- Earnings yield
- 1.4%
- 52-week high
- ₹1,701.55
- 52-week low
- ₹1,097.65
Profitability
- Operating margin
- 30.7%
- Net margin
- 20.2%
- EBITDA margin
- 32.9%
- ROE
- 11.9%
- ROCE
- 8.9%
- ROA
- 5.6%
- Dividend payout
- 0.0%
- Tax rate
- 9.0%
- Other income, % of PBT
- 10.0%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,698 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 14.2%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 7.8%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹489 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -6.3%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -74.3%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 0.6%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹336 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 4.3%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹32.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 92.2%
Solvency and efficiency
- Current ratio
- 15.09
- Debt / Equity
- 1.02
- Debt / Assets
- 0.48
- Debt / EBITDA
- 5.26
- Interest coverage
- 8.00
- Financial leverage
- 2.12
- CFO / Net profit
- 1.12
- Cash / Market cap
- 11.0%
- Cash per share
- ₹162.44
- Asset turnover
- 0.28
- Fixed asset turnover
- 0.98
- Capital intensity
- 1.02
- Debtor days
- 59 days
- Inventory turnover
- 3.07
- Cash conversion cycle
- 35 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹5 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹1,211 Cr |
| Sales | Operating profit | ₹487 Cr |
| Operating profit | Interest | ₹220 Cr |
| Operating profit | Depreciation | ₹182 Cr |
| Operating profit | Profit before tax | ₹85 Cr |
| Other income | Profit before tax | ₹35 Cr |
| Profit before tax | Tax and other | ₹43 Cr |
| Profit before tax | Net profit | ₹77 Cr |
Revenue and net profit
Revenue grew 14.2% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹1,109 Cr | ₹351 Cr |
| FY2022 | ₹1,216 Cr | ₹417 Cr |
| FY2023 | ₹1,331 Cr | ₹398 Cr |
| FY2024 | ₹1,487 Cr | ₹300 Cr |
| FY2025 | ₹1,698 Cr | ₹77 Cr |
Cash flows
FY2025: ₹702 Cr from operations, ₹343 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹395 Cr | ₹47 Cr |
| FY2022 | ₹369 Cr | ₹101 Cr |
| FY2023 | ₹322 Cr | -₹191 Cr |
| FY2024 | ₹336 Cr | -₹2,156 Cr |
| FY2025 | ₹702 Cr | ₹343 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,698 Cr+14.2%1Y
- Net profit
- ₹77 Cr-74.3%1Y
- Cash from operations
- ₹702 Cr
- Free cash flow
- ₹343 Cr
- Revenue CAGR, 5Y
- 7.8%
- EBITDA CAGR, 5Y
- 5.7%
- Net profit CAGR, 5Y
- 0.6%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,698 Cr | ₹487 Cr | — | ₹77 Cr | ₹702 Cr | ₹343 Cr | 3.1% | +14.2% | -74.3% |
Monthly returns
Month-by-month returns of ERIS across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹5,222 Cr |
| Equity capital | ₹14 Cr |
| Reserves | ₹2,501 Cr |
| Borrowings | ₹2,245 Cr |
| Other liabilities | ₹463 Cr |
| Assets | ₹5,222 Cr |
| Fixed assets | ₹2,412 Cr |
| Capital work in progress | ₹0 Cr |
| Investments | ₹991 Cr |
| Other assets | ₹1,819 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
ERIS trades at 71.4x earnings against a peer median of 52.6x (a 36% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Eris Lifesciences LimitedERISthis companyP/E ↑ premium | ₹20,131 Cr | 71.4x | 7.3x | 11.9% | 45.5x |
| Wockhardt LtdWOCKPHARMA | ₹22,539 Cr | 160.0x | 7.8x | -23.5% | -2690.8x |
| PIRAMAL PHARMA LIMITEDPPLPHARMA | ₹22,363 Cr | 31.7x | 2.9x | 5.8% | 27.6x |
| Pfizer Ltd.PFIZER | ₹22,230 Cr | 31.5x | 5.8x | 15.3% | 26.2x |
| AstraZeneca Pharma India Ltd.ASTRAZEN | ₹20,549 Cr | 88.9x | 25.7x | 22.8% | 86.6x |
| Onesource Specialty Pharma LimitedONESOURCE | ₹20,295 Cr | 76.8x | 3.4x | -98.0% | -92.4x |
| Sai Life Sciences LimitedSAILIFE | ₹19,113 Cr | 67.7x | 8.2x | 9.4% | 62.4x |
| Neuland Laboratories Limited.NEULANDLAB | ₹18,376 Cr | 94.3x | 11.4x | 23.5% | 38.6x |
| Ventive Hospitality LimitedVENTIVE | ₹17,846 Cr | 91.9x | 3.9x | 49.7% | 60.7x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
ERIS since 1 January, against earlier years.
Historical volatility
ERIS's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 38.0% |
| FY2022 | 40.0% |
| FY2023 | 38.0% |
| FY2024 | 31.0% |
| FY2025 | 29.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,698 Cr |
| Costs | |
| Interest | ₹220 Cr |
| Expenses | ₹1,210 Cr |
| Operating profitOperating Profit | ₹487 Cr |
| Other income and charges | |
| Profit before tax | ₹120 Cr |
| Tax | |
| Net profitNet Profit | ₹77 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹5,222 Cr |
| Equity capitalEquity Capital | ₹14 Cr |
| Reserves | ₹2,501 Cr |
| Borrowings | ₹2,245 Cr |
| Other liabilitiesOther Liabilities | ₹463 Cr |
| AssetsTotal Assets | ₹5,222 Cr |
| Fixed assetsFixed Assets | ₹2,412 Cr |
| Capital work in progressCWIP | ₹0 Cr |
| Investments | ₹991 Cr |
| Other assetsOther Assets | ₹1,819 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹702 Cr |
| Investing cash flowCash from Investing Activity | -₹359 Cr |
| Financing cash flowCash from Financing Activity | -₹310 Cr |
| Change in cashNet Cash Flow | ₹32 Cr |
Learn while you research
Academy chapters picked for Eris Lifesciences Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 71.4, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read